A recent experimental study showed that genetic or pharmacological blockade of pattern recognition receptor signaling via HMGB1 and receptor for advanced glycation end products (RAGE) abrogated cellular immunosuppression and restored lymphocyte activation in the subacute phase after stroke [53]. This evidence concerns the gene HMGB1 and stroke disorder.